Selected Publications for Antibody-Drug Conjugates

As a new wave of novel immune therapeutic agents, antibody-drug conjugates (ADCs) harness the powers of both the monoclonal antibody for directionality and the extremely toxic payload for tumor elimination. With two FDA-approved ADCs on the market and more than 60 emerging ADCs under clinical evaluation, the world is embracing a new era of targeted anti-tumor immune therapies. As a leading service provider in ADC development, Creative Biolabs has established a comprehensive service pipeline to help promote your ADC projects. In this section, we would like to share some excellent reference articles in the ADC field to promote the understanding and appreciation of these next-generation “magic bullets with toxic warheads”.


  • Reviews
  • ADC Payloads
  • ADC Linkers
  • ADC Conjugation Strategies
  • Multi-spectrum Evaluations of ADCs

Dozens of review articles are available covering the progression of ADC research field and various aspects in ADC development. Here we select a few reviews to represent the field in general and also focusing on intellectual property issues and marketing status of ADCs

Beck, A., Goetsch, L., Dumontet, C., Corvaïa, N. Strategies and Challenges for the Next Generation of Antibody-Drug Conjugates. Nat. Rev. Drug Discov. 2017, 16: 315-337. PubMed ID: 28303026

This article provides a comprehensive and updated review of the progressions in ADC development, covering a wide topic including the basis for ADC, the chemical compounds involved in most ADC development, conjugation technologies, as well as a full list of ADCs in clinical evaluation and on the market.

Chari, R.V.J., Miller, M.L., Widdison, W.C. Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy. Angew. Chem. Int. Ed. 2014, 53: 3796-3827. PubMed ID: 24677743

This article reviews the chemical aspects of the first and second generation of ADC payloads and payload-linker complexes. The authors presented an extensive body of knowledge regarding the payload drug efficacy, linker selection, bio-conjugation method, as well as ADC potency evaluations.

Srinivasarao, M., Galliford, C.V., Low, P.S. Principles in the Design of Ligand-Targeted Cancer Therapeutics and Imaging Agents. Nat. Rev. Drug Discov. 2015, 14: 203-219. PubMed ID: 25698644

This article provides a general guideline in the designing of efficient targeting entities that employs an antibody as the guiding molecule. The authors focused on strategies in designing and preparing biochemically compatible linkers as well as in modifying antibodies to facilitate conjugation.

Storz, U. Antibody-Drug Conjugates: Intellectual Property Considerations. mAbs. 2015, 7: 989-1009. PubMed ID: 26292154

This article focuses on the intellectual property (IP) issues involved in ADC development. The author gave a detailed explanation about the complicated entanglement of the IP issues associated with different components of an ADC, including the antibody, linker, payload, as well as the payload-linker complex.

The Therapeutic Monoclonal Antibody Market

Ecker, D.M., Jones, S.D., Levine, H.L. The Therapeutic Monoclonal Antibody Market. mAbs. 2015, 7: 9-14. PubMed ID: 25529996

This article provides an overview of the expanding therapeutic antibody market and points out a clear increase in the revenue of monoclonal antibody and monoclonal antibody associated therapeutic, including ADCs.

Sassoon, I., Blanc, V. Antibody-drug Conjugate (ADC) Clinical Pipeline: A Review. Methods Mol Biol. 2013, 1045: 1-27. PubMed ID: 23913138

This review article provides a general description of the ADCs in clinical trial pipeline back in 2013. Even though updates have been made to renew the list, the strategies for clinical trial set-up, stage design, and execution described in this paper is quite important in planning such work.


Online Inquiry
Name:
*Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
*Project Description:
*Verification Code:
Please input "biolabs"(case insensitive) as verification code.


Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.


Contact us
 45-1 Ramsey Road, Shirley, NY 11967, USA
 Tel: 1-631-381-2994
 Fax: 1-631-207-8356
 Email:

Inquiry

Top